Hylatopic Plus

Hylatopic Plus is a prescription product that appears to be very efficient and safe in treating atopic dermatitis.

Images


Effects


Grade Level of Evidence
A Double-blind, controlled study with more than 50 participants.
B Controlled study that is single-blind or has less than 50 participants.
C Controlled or comparative study.
D Uncontrolled or observational study.
Grade Effect Size of Effect Comments

C

Dermatitis treatment

Strong

Cleared or almost cleared 82% of target lesions within 4 weeks of treatment.

Looking to buy Hylatopic Plus?

Buy from Amazon.com.

Ingredients


NAME ANTIOXIDANT UV PROTECTION COMEDOGENIC IRRITANT SAFETY
SODIUM HYALURONATE (HUMECTANT, SKIN CONDITIONING) 0 (SEE SOURCES) 0 (SEE SOURCES) ALLOWED (SOURCE)

Clinical Studies


Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis.

Products

Elidel

Hylatopic Plus

Trial Design

Investigator-blinded, bilateral, comparative

Duration

4 weeks of treatment

Subjects

30 men and women suffering from mild to moderate atopic dermatitis, with symptoms on the extremities and symmetrical target eczematous areas on opposite sides of the body.

Regimen

Applied a thin layer of Elidel cream on the target area on one side of the body twice daily, and applied Hylatopic foam three times daily on a symmetrical target area on the opposite side of the body.

Bathing and showering were not allowed for at least 8 hours after application.

Methods of Assessment

Investigator's global assessment of disease severity on a 6-point scale.

Scoring of target lesion symptoms on a 4-point scale.

Photography for recording of the location and size of the target areas.

Patient self-assessments of disease control on a 4-point scale.

Side Effects

None reported.

Conflicts of Interest

Study was funded by Onset Dermatologics, which markets Hylatopic Plus. None of the authors had any financial conflicts of interest.

Effects observed in this study:

Treatment with Hylatopic foam cleared or almost cleared 82% of target lesions. The proportion was slightly lower for treatment with Elidel cream, at 71%. Investigator scores reflected a 63.1% improvement for Elidel cream, and a 67.9% improvement for Hylatopic foam.